Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 8;25(1):194.
doi: 10.1186/s10194-024-01904-1.

Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis

Wattakorn Laohapiboolrattana #  1 , Priabprat Jansem #  2 , Prakit Anukoolwittaya  3   4   5 , Duangnapa Roongpiboonsopit  1 , Akarin Hiransuthikul  6   7 , Thanakit Pongpitakmetha  6   8   9 , Sekh Thanprasertsuk  6   10   9 , Wanakorn Rattanawong  6   11   9
Affiliations

Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis

Wattakorn Laohapiboolrattana et al. J Headache Pain. .

Abstract

Background: Novel abortive treatments for migraine, ditans and gepants, have promising implications in triptan-insufficient responders with minimal existing comparative data. Our study aims to synthesize evidence through a systematic review and network meta-analysis to assess the comparative efficacy of lasmiditan, rimegepant and ubrogepant in triptan-insufficient responders.

Method: We searched PubMed, Embase, CENTRAL, and EBSCO Open Dissertations up to May 2024. We included randomized controlled trials (RCTs) that compared novel abortive treatments, including lasmiditan, rimegepant, and ubrogepant, in migraine patients who self-reported insufficient response to triptans. Outcomes are represented using relative risks with corresponding 95% confidence intervals (CI). The surface under the cumulative ranking curve (SUCRA) was used to rank each medication.

Results: A total of five phase 3 RCTs involving 3,004 patients were included in the analysis. All three agents were significantly superior to placebo for two-hour pain freedom (RR = 1.93, 95% CI [1.52, 2.46]), freedom from the most bothersome symptoms at two hours (RR = 1.55, 95% CI [1.37, 1.75]), and pain relief at two hours (RR = 1.46, 95% CI [1.35, 1.58]). No statistically significant differences in efficacy outcomes were observed among the three agents. However, lasmiditan 200 mg had the highest cumulative probability for two-hour pain freedom and relief (SUCRA 0.9, 0.8, respective), while rimegepant led in relieving the most bothersome symptoms (SUCRA 0.7).

Conclusion: Lasmiditan, rimegepant, and ubrogepant are effective for acute treatment of migraine in triptan-insufficient responders, with high-dose lasmiditan showing the highest efficacy for pain control.

Keywords: Abortive Treatment; Gepant; Lasmiditan; Rimegepant; Triptan-Insufficient Responder; Ubrogepant.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA diagram
Fig. 2
Fig. 2
Forest plot comparing the efficacy outcomes of novel abortive therapies versus placebo
Fig. 3
Fig. 3
Network map of the efficacy outcomes among novel abortive therapies and placebo
Fig. 4
Fig. 4
Treatment ranking based on SUCRA of efficacy outcomes
See this image and copyright information in PMC

References

    1. Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S et al (2024) International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia 44(8):3331024241252666 - PubMed
    1. Viana M, Genazzani AA, Terrazzino S, Nappi G, Goadsby PJ (2013) Triptan nonresponders: do they exist and who are they? Cephalalgia 33(11):891–896 - PubMed
    1. Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Uludüz D et al (2022) European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain 23(1):133 - PMC - PubMed
    1. Lombard L, Farrar M, Ye W, Kim Y, Cotton S, Buchanan AS et al (2020) A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain 21(1):41 - PMC - PubMed
    1. Marcus SC, Shewale AR, Silberstein SD, Lipton RB, Young WB, Viswanathan HN et al (2020) Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. Cephalalgia 40(7):639–649 - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources